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ABSTRAK
Latar belakang: peningkatan cakupan terapi antiretroviral (ART) merupakan penyebab utama penurunan 
mortalitas akibat faktor terkait acquired immune deficiency syndrome (AIDS). Akan tetapi, timbulnya transmitted 
drug resistance (TDR) mempersempit pilihan ART yang efektif bagi individu yang belum pernah memperoleh terapi 
(ART-naive), yang mana dapat menghambat kesuksesan terapi. Bali menempati peringkat ke-enam sebagai provinsi 
di Indonesia dengan jumlah kasus kumulatif infeksi HIV tertinggi. Tujuan penelitian ini untuk mengidentifikasi 
adanya TDR pada individu ART-naive di Kabupaten Buleleng, Bali. Metode: tiga puluh sembilan individu ART-
naive berpartisipasi dalam studi ini. Analisis genotipik dilakukan terhadap sampel darah yang diperoleh dari 
partisipan. Hasil: 28 gen protease (PR) dan 30 gen reverse transcriptase (RT) dari 37 sampel berhasil dianalisis. 
Subtyping menunjukkan CRF01_AE sebagai circulating recombinant yang paling dominan di Kabupaten Buleleng, 
Bali. TDR terhadap inhibitor PR tidak ditemukan, akan tetapi TDR terhadap inhibitor RT teridentifikasi pada 
lima dari 30 individu (16,7%). Kesimpulan: adanya TDR pada individu ART-naive di Kabupaten Buleleng, Bali, 
perlu diperhatikan karena dapat menghambat keberhasilan terapi dan mempersempit pilihan terapi yang efektif. 
Surveilans berkesinambungan perlu dilakukan untuk monitoring TDR pada individu ART-naive.
Kata kunci: HIV-1, CRF01_AE, Bali, antiretroviral therapy (ART), transmitted drug resistance (TDR).
ABSTRACT
Background: the global scale-up of antiretroviral therapy (ART) is the primary factor contributing to the 
decline in deaths from acquired immune deficiency syndrome (AIDS)-related illnesses. However, the emergence of 
transmitted drug resistance (TDR) compromises the effects of ART in treatment-naïve individuals, which may hinder 
treatment success. The present study aimed to identify the presence of TDR among treatment-naive individuals in 
Buleleng, Bali, which is currently ranked sixth among Indonesian provinces with the highest cumulative human 
immunodeficiency virus type 1 (HIV-1) infection cases. Methods: thirty-nine ART-naive individuals in Buleleng 
Regency General Hospital were enrolled in the present study. Blood samples from participants were subjected to a 
genotypic analysis. Results: 28 protease (PR) and 30 reverse transcriptase (RT) genes were successfully amplified 
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and sequenced from 37 samples. HIV-1 subtyping revealed CRF01_AE as the dominant circulating recombinant 
form in the region. No TDR for PR inhibitors was detected; however, TDR for RT inhibitors was identified in five out 
of 30 samples (16.7%). Conclusion: these results indicate the emergence of TDR among ART-naive individuals in 
Buleleng, Bali. This issue warrants serious consideration because TDR may hamper treatment success and reduce 
ART efficacy among newly diagnosed individuals. Continuous surveillance with a larger sample size is necessary 
to monitor TDR among ART-naive individuals.
Keywords: HIV-1, CRF01_AE, Bali, antiretroviral therapy (ART), transmitted drug resistance (TDR).
INTRODUCTION
The Joint United Nations Programme on 
human immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) (UNAIDS) 
reported a marked reduction in deaths from AIDS-
related illnesses, from a peak of 1.9 million in 
2004 to 940,000 in 2017. The global scale-up 
of antiretroviral therapy (ART) is the primary 
factor contributing to the decline in deaths.1 
Combination ART decreases the replication 
of HIV type 1 (HIV-1), thereby improving the 
survival of infected individuals and lowering the 
risk of transmission.2,3
UNAIDS estimated a decline in new HIV 
infections in Indonesia, from 62,000 cases in 
2005 to 49,000 cases in 2017.1 The Indonesian 
Ministry of Health reported 280,623 cumulative 
HIV infection cases up to December 2017, with 
102,667 cumulative AIDS cases. Provinces with 
the highest cumulative HIV infection and AIDS 
cases include DKI Jakarta, East Java, Papua, 
West Java, Central Java, and Bali.4
HIV-1, which is responsible for most of the 
global HIV pandemic, has been subdivided into 
group M (major), group O (outlier), group N (non-
major, non-outlier), and new group P (pending). 
Group M, the pandemic group of HIV-1, has been 
further divided into subtypes A to K. Besides 
these subtypes, circulating recombinant forms 
(CRFs) and unique recombinant forms (URFs), 
as a result of recombination among 2 or more 
subtypes and/or CRFs, have also been identified 
in group M. CRF01_AE, the second predominant 
circulating CRF accounting for 5% of infection 
cases worldwide in 2004-2007, is responsible for 
the vast majority of infections in Southeast Asia, 
including several regions in Indonesia.5–10
In December 2017, 91,369 Indonesians were 
receiving ART; 88,386 among them received 
a first-line regimen, and 2,983 a second-line 
regimen.4 First-line ART regimens comprise two 
nucleoside reverse transcriptase (RT) inhibitors 
(NRTIs) and a non-nucleoside RT inhibitor 
(nNRTI), while two NRTIs plus a ritonavir-
boosted protease (PR) inhibitor (PI) are adopted 
for second-line regimens.11
Although ART is successful in Indonesia in 
reducing AIDS case fatality rate since 2004, the 
emergence of drug resistance has been reported 
not only among ART-experienced individuals, 
but also among newly diagnosed, ART-naive 
individuals.6–10 The emergence of drug resistance-
associated mutations (DRMs) compromises the 
effectiveness of ART, resulting in lower viral 
suppression and hinders treatment success.12 
Several DRMs in the HIV-1 pol gene are known 
to reduce viral susceptibility towards treatment, 
particularly a first-line regimens combining a 
NRTI and nNRTI.13 Thus, the presence of DRMs 
may be a cause for concern in various countries 
including Indonesia, where 88,386 out of 91,369 
individuals on ART (96.7%) receive a first-line 
regimen11, and thus rely heavily on ART with 
first-line regimens for the treatment of HIV-1.4 
The emergence of transmitted drug resistance 
(TDR) is attributed to the transmission of 
a drug-resistant virus.14 TDR compromises 
the effectiveness of ART for treatment-naïve 
individuals.15 Our previous studies revealed the 
appearance of TDR for RT inhibitors among 
4.3% (2/47) and 12.9% (4/31) of ART-naive 
individuals residing in Surabaya and West 
Papua, respectively.9,10 Bali, a popular tourism 
destination,16 is now ranked sixth among 
Indonesian provinces with the highest cumulative 
HIV cases, and ranks fifth for cumulative AIDS 
cases.4 Acquired drug resistance were previously 
reported to be found in 10% of ART-experienced 
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individuals in Buleleng, a regency located in the 
northern of Bali.17 The present study aimed to 
identify the presence of TDR among ART-naive 
individuals in Buleleng, Bali.
METHODS
We determined the necessary sample size 
by consulting with a statistic lecturer at the 
Faculty of Medicine, Universitas Airlangga, and 
recruited 39 individuals recently diagnosed with 
HIV-1 infection at the Voluntary Counselling 
and Testing Clinic of Buleleng Regency 
General Hospital, Bali. Five milliliters of 
ethylenediaminetetraacetic acid (EDTA)-
anticoagulated peripheral blood samples were 
collected from study participants in February 
2018. DNA was then extracted from whole 
blood samples using the Wizard® Genomic 
DNA Purification Kit (Promega, Madison, WI, 
USA). Demographic and clinical data on study 
participants were retrieved from medical records.
Amplification of HIV-1 Genomic Fragments
Viral pol gene encoding full-length PR 
(PR gene) and RT (RT gene) was amplified 
from DNA extracted from peripheral blood 
samples by the nested polymerase chain 
reaction (PCR) using GoTaq Green Master 
Mix (Promega, Madison, WI, USA) and the 
following primers. The primers DRPRO5, 
5´-AGACAGGYTAATTTTTTAGGGA-3´ 
[corresponding to nucleotides (nt) 2074-2095 
of the HIV-1 reference strain, HXB2 (GenBank 
accession no. K03455)] and DRPRO2L, 
5´-TATGGATTTTCAGGCCCAATTTTTGA-3´, 
(nt  2716 to 2691) were used in f i rs t 
PCR for  the amplif icat ion of  the PR 
g e n e ,  a n d  t h e  p r i m e r s  D R P R O 1 M , 
5´-AGAGCCAACAGCCCCACCAG-3´ (nt 
2148 to 2167) and DRPRO6, 5´-ACTTTT 
GGGCCATCCATTCC-3´ (nt 2611 to 2592) 
were used for nested PCR. The primers RT1L, 
5’-ATGATAGGGGGAATTGGAGGTTT-3’ 
(nt 2388 to 2410) and GPR2M, 5’-GGACTA 
CAGTCYACTTGTCCATG-3’ (nt  4402 
to 4380) were used in first PCR for the 
amplification of the RT gene, while RT7L, 
5’-GACCTACACCTGTCAACATAATTGG-3’ 
(nt 2485 to 2509) and GPR3L, 5’-TTAAAA 
TCACTARCCATTGYTCTCC-3’ (nt 4309 to 
4285) were used for nested PCR.
Sequencing Analysis, HIV-1 Subtyping, and 
Detection of Drug Resistance-associated 
Mutations
Successfully amplified viral PR and RT genes 
were subjected to a sequence analysis performed 
by Macrogen South Korea (http://dna.macrogen.
com). Sequencing data were assembled and 
aligned using Genetyx version 10 software 
(Genetyx, Tokyo, Japan). HIV-1 subtyping 
was then conducted using the Recombinant 
Identification Program (RIP) available on the 
HIV sequence database website (www.hiv.lanl.
gov)17 and jumping profile Hidden Markov 
Model (jpHMM) (http://jphmm.gobics.de/
submission_hiv).18 In addition, neighbor-joining 
(NJ) trees with a Kimura two-parameter model 
were constructed using MEGA 6.2 software with 
bootstrap values (1,000 replicates) for relevant 
nodes being reported on a representative tree. The 
appearance of DRMs in successfully sequenced 
PR and RT genes was analyzed according to the 
International Antiviral Society-USA (IAS-USA) 
panel.13 The nucleotide sequences of viral gene 
fragments have been deposited in the GenBank 
database under accession numbers MK656030-
MK656087.
Ethics Statement
Ethical approval for this research was 
obtained from the Ethics and Law Committee of 
Universitas Airlangga Hospital (Ethical approval 
no. 033/KEH/2016) and the Institutional Ethics 
Committee of Kobe University Graduate 
School of Medicine (approval no.: 784). Written 
informed consent was obtained from all study 
participants prior to sample collection.
RESULTS
Demographic and Clinical Information on 
Study Participants
All participants were confirmed to be 
ART-naive from medical records. Twenty-four 
(66.7%) participants were male. The youngest 
participants were 16 years old and the oldest 
was 47 years old, with the most predominant age 
group being 30-34 years old. Fifteen individuals 
(38.5%) were co-infected with tuberculosis 
(TB). Regarding the clinical stage of HIV 
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infection, 9 (23.1%), 18 (46.2%), and 12 (30.8%) 
individuals were classified as stages 2, 3, and 4, 
respectively. Among participants, 11 (28.2%) 
were underweight (body mass index <18.5). 
The demographic and clinical data of 39 study 
participants are shown in Table 1.
TDR was detected in PR genes; however, several 
minor mutations were detected. Among 28 PR 
genes, 10 (35.7%) contained L10I/V [amino 
acid substitution from leucine (L) to isoleucine 
(I) or valine (V) at position 10 in the PR gene], 
12 (42.9%) G16E, 11 (39.3%) K20R/I, 28 
(100%) M36I, one (3.6%) D60E, eight (28.6%) 
L63P, 26 (92.9%) H69K, one (3.6%) A71V, one 
(3.6%) V77I, six (21.4%) V82I, 28 (100%) L89I, 
and 10 (35.7%) I93L. M36I, H69K, and L89I, 
which presented in more than 90% samples, are 
common polymorphisms in non-B subtypes, 
including CRF01_AE.19
Five out of 30 samples (16.7%) possessed 
TDR in the RT genes. The demographic 
characteristics of individuals with major DRMs 
in RT genes are shown in Table 2. The E138G/A 
mutation was detected in 2 samples (6.24%), 
while other major mutations, including K103N, 
G190A, and K219Q, were each found in one 
sample (3.12%). Besides the major DRMs, minor 
mutations were detected in 4 samples (13.3%), 
including V90I (3.12%), V106I (3.12%), and 
V179D/F (6.24%).
DISCUSSION
We herein report the circulating HIV-1 
subtype and prevalence of TDR among HIV-
1-infected, ART-naive individuals residing in 
Buleleng, Bali, Indonesia. Among 37 successfully 
sequenced samples, 36 (97.3%) were classified 
as CRF01_AE, and the remainder (2.7%) as 
CRF02_AG. These results are consistent with 
previous findings for the predominance of 
CRF01_AE in various regions in Indonesia.6–10 
However, the HIV-1 gene fragments analyzed in 
the present study were insufficient to identify the 
actual CRF since recombinant forms of HIV-1 
possibly contain various sequences derived from 
more than 2 different subtypes and/or CRFs. 
Therefore, full-genomic sequencing analyses 
of the HIV-1 genome must be carried out in a 
future study.
A genotypic drug resistance study revealed 
no evidence of circulating PI-related TDR 
in Buleleng. This may have been due to the 
limited usage of PIs in this region. Among 
ART-experienced individuals in Indonesia, only 
3.3% (2,983 of 91,369) were receiving a PI-
Table 1. Demographic and clinical data of ART-naïve 
individuals in Buleleng regency, Bali
Variables n (%)
Sex
 - Male 24 (66.7)
 - Female 15 (41.7)
Age (years)
 - 15-19 4 (10.3)
 - 20-24 6 (15.4)
 - 25-29 8 (20.5)
 - 30-34 9 (23.1)
 - 35-39 8 (20.5)
 - 40-44 3 (7.7)
 - 45-49 1 (2.6)
Clinical stage
 - II 9 (23.1)
 - III 18 (46.2)
 - IV 12 (30.8)
TB co-infection
 - Yes 15 (38.5)
 - No 24 (61.5)
Underweight
 - Yes (BMI <18.5) 11 (28.2)
 - No (BMI ≥18.5) 28 (71.8)
TB, tuberculosis; BMI, body mass index
HIV-1 Subtyping
Sequencing data were successfully obtained 
from 37 out of 39 samples, comprising 28 PR 
genes (297-bp; nt 2253 to 2549) and 30 RT genes 
(1680-bp; nt 2550 to 4229). HIV-1 subtyping 
by RIP and jpHMM was consistent with that by 
NJ trees (data not shown). Thirty-six samples 
(97.3%) were classified as CRF01_AE, while 
a sample (2.7%) was classified as CRF02_AG. 
The NJ trees of the PR and RT genes are shown 
in Figure 1.
Appearance of DRMs
TDR was defined as the presence of at 
least one major DRM listed in the International 
AIDS Society United States (IAS-USA) panel 
database.13 Regarding the results obtained, no 
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Figure 1. Phylogenetic tree analysis of HIV-1 PR and RT gene sequences collected from ART-naive individuals in Buleleng, 
Bali, Indonesia. Phylogenetic trees were constructed for the HIV-1 PR (A) and RT (B) genes newly sequenced in the present 
study. The corresponding viral genes of reference HIV-1 strains representing subtypes A1, A2, B, C, D, and G, as well as 
CRF01_AE (01_AE) and CRF02_AG (02_AG) were included in the analyses (shown in bold). Sequence IDs are presented as 
a sample ID or the ID of the reference HIV-1 strain, a GenBank accession number, and the subtype or CRF of the reference 
strain (shown in parentheses) in that order. Bootstrap values were shown if they were >70.
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based regimen in 2017. Although no TDR was 
detected in PR genes, minor mutations, including 
L10I/V, G16E, K20R/I, M36I, D60E, L63P, 
H69K, A71V, V77I, V82I, L89I, and I93L, were 
identified in the present study. These mutations 
potentially affect viral susceptibility to ritonavir-
boosted atazanavir (ATV/r), ritonavir-boosted 
fosamprenavir (FPV/r), ritonavir-boosted 
indinavir (IDV/r), ritonavir-boosted lopinavir 
(LPV/r), nelfinavir (NFV), ritonavir-boosted 
saquinavir (SQV/r), and ritonavir-boosted 
tipranavir (TPV/r).13 The presence of these minor 
mutations needs to be taken into cosideration 
because LVP/r, which is recommended by the 
Indonesian Ministry of Health as a second-line 
regimen of ART11, is potentially affected.
In contrast, the prevalence of TDR against 
RT inhibitors was 16.7% (5/30), which is 
higher than that reported in previous studies in 
Surabaya (4.3%; 2/47) and West Papua (12,9%; 
5/31).9,10 Identified TDR, including E138G/A, 
K103N, G190A, and K219Q, may affect 
nNRTIs, such as rilpivirine (RPV), efavirenz 
(EFV), nevirapine (NPV), and etravirine (ETV), 
and NRTIs, including zidovudine (AZT) and 
stavudine (d4T). K219Q, which is also known 
as a thymidine analogue-associated mutation 
(TAM), is associated with multi-NRTI resistance, 
excluding emtricitabine (FTC) and lamivudine 
(3TC). AZT, EFV, and NPV are included as 
recommended options for individuals starting 
first-line ART in Indonesia;11 thus, the presence 
of TDR affecting these inhibitors need to be 
considered. Minor mutations, including V90I, 
V106I, and V179D/F, were also detected. These 
minor mutations may affect ETV.13
Based on clinical data, 38.5% ART-naive 
individuals were co-infected with TB. TB is 
regarded as the leading opportunistic disease 
and cause of death in individuals with HIV 
infection.20,21 Regarding the nutritional status, 
28.2% individuals were underweight. Low BMI 
is correlated with mortality in HIV-infected 
individuals,21–23 as higher BMI and fat mass 
among ART-naïve individuals were reported to 
be associated with slower disease progression.24 
A previous study reported that women who 
were underweight prior to ART died from 
AIDS more than twice as rapidly than normal 
weight women.25 As for the clinical stage of 
HIV infection, 46.2 and 30.8% individuals were 
classified as stages 3 and stage 4, respectively. 
Higher clinical stages were correlated with 
higher mortality in HIV-infected individuals.21,22
The results of the present study indicate 
the emergence of TDR among ART-naive 
individuals in Buleleng, Bali. In the WHO 
TDR surveillance guidelines, the prevalence 
of TDR is categorized into three groups: low 
level (<5%), moderate level (5–15%), and high 
level (>15%).26 According to this guideline, the 
prevalence of TDR in Buleleng is considered 
to be high level, indicating inadequate first-line 
regimens. However, the present results may have 
overestimated the prevalence of TDR because 
there were several limitations in the design of 
the study. The WHO guidelines aim to recruit 
recently infected individuals (younger than 25 
years of age and CD4+ T-cell counts higher than 
500 cells/mm3);27 however, these criteria were not 
Table 2. Demographic characteristics and drug resistance-associated major mutations in RT genes derived from ART-
naïve individuals in Buleleng Regency, Bali.
ID Age (years) Sex Subtypeb
Drug Resistance Mutationsa
NRTI nNRTI Resistance
BLL202 38 Male CRF01_AE K103N Efavirenz, nevirapine
BLL222 29 Female CRF01_AE E138A Etravirine, rilpivirine
BLL227 29 Female CRF01_AE G190A Efavirenz, etravirine, nevirapine
BLL229 47 Male CRF01_AE K209Q Multi-NRTI, stavudine, zidovudine
BLL240 23 Female CRF01_AE E138G Etravirine, rilpivirine
a Drug resistance mutations were based on guidelines published by the International Antiviral Society-USA (IAS-USA).
b The subtype of the RT gene was assigned based on RIP and phylogenic analyses.
RT, reverse transcriptase; NRTI, nucleoside reverse transcriptase inhibitor; nNRTI, non-nucleoside reverse transcriptase 
inhibitor; RIP, recombinant identification program.
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applied in the present study for practical reasons. 
The number of samples collected was also 
limited. During sample collection in February 
2018, less than 50 individuals were newly 
diagnosed with HIV infection at the Voluntary 
Counselling and Testing Clinic of Buleleng 
Regency General Hospital, Bali. Among those 
individuals, only 39 individuals were agreed 
to be enrolled in this study. We believe the 39 
samples are a minimum necessary number for 
this study. Therefore, in order to clarify and 
monitor TDR among ART-naive individuals, 
continuous surveillance with a larger sample 
size and compliance with the WHO selection 
criteria for TDR surveillance are necessary. 
Besides TDR, the presence of individuals who 
were co-infected with TB, underweight, and 
diagnosed with a higher clinical stage also need 
proper consideration, as these conditions were 
correlated with HIV-related mortality.20–25
CONCLUSION
There is the emergence of TDR was found 
among ART-naive individuals in Buleleng, 
Bali. This issue warrants serious consideration 
because TDR may hamper treatment success and 
reduce ART efficacy among newly diagnosed 
individuals. Continuous surveillance with a 
larger sample size is necessary to monitor TDR 
among ART-naive individuals.
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